

A trial investigating the effectiveness of vagus nerve stimulation during rehabilitation therapy in patients with a weak arm following a stroke

Submission date 03/11/2022	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 07/12/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 20/01/2026	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Over 15 million people suffer a stroke worldwide annually. One third are left with arm weakness causing difficulties with daily activities. Whilst rehabilitation therapy does help after stroke, the benefits are modest. In a recent trial, stimulating the vagus nerve (VN) while the participant moved their weak arm resulted in better arm recovery compared with therapy alone. However, the stimulator was surgically implanted, and the VNS was triggered by a therapist in hospital. In this study the VN will be stimulated in a non-invasive way at home. The VN will be stimulated through the skin via an earpiece using a TVNS device. This study aims to determine whether transcutaneous vagus nerve stimulation (TVNS) paired with rehabilitation therapy of the affected arm after stroke improves motor function in participants with arm weakness following a stroke. In a sub-study, the researchers will also assess if TVNS produces changes in the brain via fMRI and, in some cases, PET scans.

Who can participate?

Patients aged 18 years and over who have arm weakness following a stroke between 6 months to 10 years ago and are no longer undergoing active rehabilitation therapy

What does the study involve?

Participants will be randomly allocated to receive either sham TVNS (very low stimulation) or active TVNS. Some participants will also be asked to wear the TVNS device whilst undertaking activities of daily living. Participants will wear the TVNS device when completing the self-delivered rehabilitation therapy for 1 hour per day, 5 days per week for 12 weeks. The rehabilitation therapy plan will be tailored to each participant, completed at home, and includes repetitive tasks such as turning cards, moving objects, opening, and closing bottles. Participants will be followed up at a face-to-face appointment at 3 and 6 months after starting treatment. The follow-up appointments enable outcome assessments of the intervention.

What are the possible benefits and risks of participating?

By taking part in this study, participants will be directly helping to inform the future evidence base of interventions for people with arm weakness after stroke. Participants will be given a

tailored 12-week rehabilitation therapy programme to do at home and a TVNS device to use for the duration. This may be of benefit to some participants who may not be receiving any other therapy for their arm weakness. The TVNS device is usually well tolerated but previous studies have found some side effects. These are mild skin irritation (in 15% of cases), headaches (less than 5% of cases), dizziness, sore throat and nausea (all in less than 2% of cases). The nerve that is stimulated in this study can affect the heart rhythm but there has been lots of research using this device in humans with no concerns about the safety of the participants. Some participants may find participation in the trial time-consuming as it will require attendance at a minimum of three face-to-face appointments, in addition to the 12-week treatment period completed at home.

Where is the study run from?

About 15 stroke centres across the UK will be taking part in the study and it will be managed by the Clinical Trials Research Unit at the University of Sheffield (UK)

When is the study starting and how long is it expected to run for?

February 2022 to January 2027

Who is funding the study?

National Institute for Health and Care Research (NIHR) (UK)

Who is the main contact?

Kirsty McKendrick, kirsty.mckendrick@sheffield.ac.uk, triceps@sheffield.ac.uk

Contact information

Type(s)

Scientific

Contact name

Miss Kirsty McKendrick

Contact details

Clinical Trials Research Unit

ScHARR

The University of Sheffield

30 Regent Court

Sheffield

United Kingdom

S1 4DA

+44 (0)114 222 4308

kirsty.mckendrick@sheffield.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

308254

ClinicalTrials.gov (NCT)

Nil known

Central Portfolio Management System (CPMS)

53862

Study information

Scientific Title

An efficacy and mechanism evaluation of transcutaneous vagal nerve stimulation for upper limb recovery post-stroke – a randomised, controlled, multi-arm, multi-stage, adaptive design trial

Acronym

TRICEPS

Study objectives

Primary hypotheses:

Hypothesis 1: Participants receiving transcutaneous vagal nerve stimulation (TVNS) plus rehabilitation therapy for 12 weeks will attain greater motor improvement compared to home rehabilitation therapy alone.

Hypothesis 2: Participants who receive TVNS while undertaking activities of daily living in addition to TVNS during rehabilitation therapy for 12 weeks will attain even greater benefit.

Secondary objectives:

Hypothesis 3: The beneficial effects of TVNS plus rehabilitation therapy will be sustained at 6 months from the start of treatment.

Hypothesis 4: TVNS will have a positive effect on other key outcome measures.

Hypothesis 5: TVNS and self-delivered home rehabilitation therapy is a safe intervention for participants.

Hypothesis 6: TVNS plus rehabilitation therapy improves cortical plasticity, cerebral blood flow and brain energy and oxygen metabolic profiles which may trigger greater improvement in motor function compared to rehabilitation therapy alone.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 12/10/2022, East of England - Cambridge Central Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, UK; +44 (0)207 104 8286; cambridgecentral.rec@hra.nhs.uk), ref: 22/EE/0209

Study design

Randomized; Interventional; Design type: Treatment, Device, Imaging, Rehabilitation

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Stroke

Interventions

Participants will be allocated to receive TVNS plus self-delivered rehabilitation therapy for 1 hour, 5 times a week for 12 weeks, or sham TVNS (the earpiece will produce negligible stimulation) plus self-delivered rehabilitation therapy for 1 hour, 5 times a week for 12 weeks. Some participants may also be asked to wear the device whilst doing activities of daily living for 1 to 8 hours on the therapy days.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Not provided at time of registration

Primary outcome(s)

Upper limb motor function assessed using the Upper Limb Fugl-Meyer (ULFM) total motor score at 3 months from the start of treatment

Key secondary outcome(s)

Measured at baseline, 3 and 6 months from the start of treatment, unless stated otherwise:

1. Upper limb motor function assessed using the ULFM total motor score at 6 months from the start of treatment
2. Sensation, joint range of motion and joint pain assessed using other components of the ULFM outcome measure
3. Motor function of the affected arm assessed using the Wolf Motor Function Test (WMFT)
4. Total stroke-related neurological deficit measured using the Modified National Institute of Health Stroke Scale (mNIHSS)
5. The degree of dependence in the daily activities of people who have had a stroke, measured using the Modified Rankin Scale (mRS)
6. Activities of daily living assessed using the Nottingham Extended Activities of Daily Living (NEADL) scale
7. Stroke-specific quality of life measured using the Stroke-Specific Quality-of-Life (SS-QOL) scale
8. Generalised anxiety disorder assessed using the General Anxiety Disorder (GAD-7) total score
9. Depression assessed using the Patient Health Questionnaire (PHQ-9) total score
10. Fatigue assessed using the Neurological Fatigue Index for stroke (NFI-Stroke)
11. Pain intensity measured using a Visual Analogue Scale (VAS)
12. Whether a participant had experienced a clinically meaningful improvement of 6 points on ULFM total motor score outcome compared to baseline

Completion date

31/12/2027

Eligibility

Key inclusion criteria

1. Aged 18 years or greater
2. Anterior circulation ischaemic stroke between 6 months and 10 years previously
3. Baseline ULFM of 20-50 (inclusive) indicating moderate to severe arm dysfunction
4. At least 10 degrees of active wrist extension, 10 degrees of active thumb abduction /extension, and 10 degrees of active extension in at least 2 additional digits
5. Able to participate in rehabilitation therapy, provide feedback on adverse events (AEs), and give appropriate informed consent based on clinical judgment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Has significant other impairment of upper limb, e.g., frozen shoulder
2. Has severe spasticity (Modified Ashworth score of ≥ 3)
3. Has health conditions that prevent engagement with rehabilitation therapy, e.g., advanced dementia
4. Has severe aphasia and either: a) informed consent unlikely based on consent support tool, b) engagement with RTT difficult, or c) inability to communicate adverse events from TVNS
5. Currently participating in another stroke rehabilitation trial
6. Pregnant or trying to get pregnant
7. On a pacemaker or another implantable electrical device
8. Has a cochlear implant or other similar device
9. Currently receiving therapy or treatment to improve arm function and would not be willing to stop for the duration of the trial
10. Has previously experienced a haemorrhagic stroke

For all participants entering the mechanistic sub-study only:

1. Contraindications to Magnetic Resonance Imaging (MRI) (e.g., metal implant)
2. Has previously experienced or is likely to suffer severe anxiety or claustrophobia in relation to MR imaging examination

Additional criteria for PET-MRI:

1. Contraindications to Positron Emission Tomography (PET) (e.g., has a known allergy to FDG)

PET tracer)

2. Has unstable diabetes

A full screening assessment will be conducted when the participant attends for the MRI to ensure the safety of the participant.

Date of first enrolment

01/10/2023

Date of final enrolment

31/07/2026

Locations

Countries of recruitment

United Kingdom

England

Wales

Study participating centre

Royal Hallamshire Hospital

Glossop Road

Sheffield

England

S10 2JF

Study participating centre

John Radcliffe Hospital

Headley Way

Headington

Oxford

England

OX3 9DU

Study participating centre

Pulross Community Centre

47a Pulross Road

Stockwell

London

England

SW9 8AE

Study participating centre
Melbourne Centre Surgery
Swithland House
352 London Road
Leicester
England
LE2 2PL

Study participating centre
Doncaster Royal Infirmary
Armthorpe Road
Doncaster
England
DN2 5LT

Study participating centre
Montagu Hospital
Adwick Road
Mexborough
England
S64 0AZ

Study participating centre
Bodmin Hospital
Boundary Road
Bodmin
England
PL31 2QT

Study participating centre
Heart of Hounslow Centre for Health
92 Bath Road
Hounslow
England
TW3 3EL

Study participating centre
St Mary's Hospital
Green Hill Road
Leeds

England
LS12 3QE

Study participating centre

Aintree Hospital

Therapies Department
Lower Lane
Fazakerley
England
L9 7AL

Study participating centre

Moseley Hall Hospital

Alcester Road
Moseley
Birmingham
England
B13 8JL

Study participating centre

St Lukes Hospital

Little Horton Lane
Bradford
England
BD5 0NA

Study participating centre

West Pottergate Medical Practice

Earlham Road
Norwich
England
NR2 4BX

Study participating centre

Sunderland Royal Hospital

Kayll Road
Sunderland
England
SR4 7TP

Study participating centre
University Hospital Llandough
Penlan Road
Llandough
Penarth
Wales
CF64 2XX

Study participating centre
Royal London Hospital
HASU (Hyper Acute Stroke Unit)
Ward 11C Research Office
Whitechapel Road
Whitechapel
London
England
E1 1FR

Study participating centre
Royal Bournemouth General Hospital
Castle Lane East
Bournemouth
England
BH7 7DW

Study participating centre
Yeatman Hospital
Hospital Lane
Sherborne
England
DT9 3JU

Study participating centre
South Petherton Community Hospital
Bernard Way
South Petherton
England
TA13 5EF

Study participating centre

Royal Hallamshire Hospital
Glossop Road
Sheffield
England
S10 2JF

Study participating centre
Royal Bolton Hospital
Minerva Road
Farnworth
Bolton
England
BL4 0JR

Sponsor information

Organisation
Sheffield Teaching Hospitals NHS Foundation Trust

ROR
<https://ror.org/018hjpz25>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health and Care Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Funder Name

NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR133169

Results and Publications

Individual participant data (IPD) sharing plan

Requests for patient level data and statistical code should be made to the corresponding author and will be considered by members of the original trial management group, including the chief investigator and members of CTRU, who will release data on a case by case basis. Data will be shared following the principles for sharing patient level data as described by Smith et al (2015) [1]. The data will not contain any direct identifiers, we will minimise indirect identifiers and remove free text data, to minimise the risk of identification.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		26/03/2025	22/09/2025	Yes	No
HRA research summary			28/06/2023	No	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes
Study website	Study website	11/11/2025	11/11/2025	No	Yes